2026-04-29T15:24:42Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/192592024-09-27T07:57:47Zcom_20.500.12105_19604com_20.500.12105_2051col_20.500.12105_19605

00925njm 22002777a 4500 dc Brito, Dulce author Albrecht, Fabiano Castro author de Arenaza, Diego Perez author Bart, Nicole author Better, Nathan author Carvajal-Juarez, Isabel author Conceição, Isabel author Damy, Thibaud author Dorbala, Sharmila author Fidalgo, Jean-Christophe author Garcia-Pavia, Pablo author Ge, Junbo author Gillmore, Julian D author Grzybowski, Jacek author Obici, Laura author Piñero, Daniel author Rapezzi, Claudio author Ueda, Mitsuharu author Pinto, Fausto J author 2023 Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive and fatal condition that requires early diagnosis, management, and specific treatment. The availability of new disease-modifying therapies has made successful treatment a reality. Transthyretin amyloid cardiomyopathy can be either age-related (wild-type form) or caused by mutations in the TTR gene (genetic, hereditary forms). It is a systemic disease, and while the genetic forms may exhibit a variety of symptoms, a predominant cardiac phenotype is often present. This document aims to provide an overview of ATTR-CM amyloidosis focusing on cardiac involvement, which is the most critical factor for prognosis. It will discuss the available tools for early diagnosis and patient management, given that specific treatments are more effective in the early stages of the disease, and will highlight the importance of a multidisciplinary approach and of specialized amyloidosis centres. To accomplish these goals, the World Heart Federation assembled a panel of 18 expert clinicians specialized in TTR amyloidosis from 13 countries, along with a representative from the Amyloidosis Alliance, a patient advocacy group. This document is based on a review of published literature, expert opinions, registries data, patients' perspectives, treatment options, and ongoing developments, as well as the progress made possible via the existence of centres of excellence. From the patients' perspective, increasing disease awareness is crucial to achieving an early and accurate diagnosis. Patients also seek to receive care at specialized amyloidosis centres and be fully informed about their treatment and prognosis. Glob Heart. 2023 Oct 26;18(1):59. 10.5334/gh.1262 2211-8179 Global heart 37901600 http://hdl.handle.net/20.500.12105/19259 World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM).